Experimental stem cell infusions offered to elderly Parkinson's patients
NCT ID NCT04772378
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 19 times
Summary
This expanded access program tested the safety of multiple intravenous infusions of a patient's own stem cells (HB-adMSCs) for treating Parkinson's disease. It involved 10 patients aged 76 to 95 who did not qualify for other studies. Each patient received 200 million stem cells over 18 weeks, followed by a 6-week safety check. The goal was to see if this approach is safe, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hope Biosciences Stem Cell Research Foundation
Sugar Land, Texas, 77478, United States
Conditions
Explore the condition pages connected to this study.